Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131144 · ClinicalTrials.gov registry record · Phase 3
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 583
- Enrollment target
NCT00131144 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 583 participants.
The verdict
NCT00131144, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 583 participants
- Enrollment target
Study Summary
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.
Interventions
- DRUG Placebo
- DRUG Octreotide Acetate in Microspheres
- DRUG Octreotide Acetate in Microspheres 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 583 participants |
| Start Date | 1999-11 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131144
The ClinicalTrials.gov registry entry for NCT00131144 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 583 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00131144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00131144 about?
NCT00131144 is a clinical study titled "Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy". The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and p...
What is the current status of trial NCT00131144?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 583 participants. The study started on 1999-11. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00131144?
The interventions under investigation include: Placebo (DRUG), Octreotide Acetate in Microspheres (DRUG), Octreotide Acetate in Microspheres 20 mg (DRUG).
Who is sponsoring clinical trial NCT00131144?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.